J&J is the split-era quality staple: MedTech vs. remaining pharma after the consumer spin. The desk uses it to test “forever hold” language against litigation and pipeline cliffs.
Smith/Buffett quality vs. Klarman legal-overhang special situation. Growth seats should be quiet unless a pipeline print is the actual thesis.
Talcum and other legal reserves, patent cliffs, and which segment still drives the 10-K after Kenvue. Confirm you are on JNJ, not the spun consumer name.
Independent briefs, then clerk assembly · 3 isolated prompts + 1 assembly pass · filing facts from SEC EDGAR (cached 7 days) — not investment advice, no buy button
Preview seating. Paid desks are 16 / 29 / 48 / 61. $49 is Associate (29), not 61. Partners is the same 61 with more compute.
Johnson & Johnson · 10-K FY · FY2025 · ended 2025-12-28 · CIK 0000200406
Filings from SEC companyfacts (us-gaap). P/B, P/S from cached price × diluted shares vs filings. Not a live quote. Not a live quote, not advice, not a buy button. Missing numbers stay blank; P/E shows n/m when diluted EPS ≤ 0.
Same file, different rules. Each brief states a view and why. Briefs are written in isolation so one loud narrative cannot drag the room. The clerk reads them only after they exist. Never “you should buy.” There is no buy button.
Constructive — the work is worth continuing, not an order. Owner test on JNJ: P/E 24.1, P/B 7.94, ROE 32.9%, net income $26.8B.
Question: “Research JNJ as a US-listed name.”. Owner earnings lens on JNJ. Plain Midwest English, folksy metaphors, long-horizon. Hard rule: Circle of competence: if the business cannot be explained simply, pass. Numbers on file: P/E 24.1; P/B 7.94; ROE 32.9%; net income $26.8B; revenue YoY 6.0%. On file: 10-K FY FY2025; revenue $94.2B; revenue YoY 6.0%; net income $26.8B; ROE 32.9%; LT debt/equity 0.51; P/E 24.1; P/B 7.9; P/S 6.9; price $266.35 cached. A low multiple that needs a hero story is not a margin of safety. A rich multiple with durable ROE can still be a business — but then price is the risk. Underwrite frame: Worth further homework.
Cautious — the file is open, the bar is not cleared. Classify JNJ before cheering growth. revenue YoY 6.0%. P/E 24.1.
Question: “Research JNJ as a US-listed name.”. Classify before multiple. Six-category company classification system.. revenue YoY 6.0%. P/E 24.1. revenue $94.2B. On file: 10-K FY FY2025; revenue $94.2B; revenue YoY 6.0%; net income $26.8B; ROE 32.9%; LT debt/equity 0.51; P/E 24.1; P/B 7.9; P/S 6.9; price $266.35 cached. Fast growth with no category is how you buy a story. Stalwart growth with a broken category is how you overstay. Underwrite frame: Worth further homework.
Cautious — the file is open, the bar is not cleared. Invert JNJ first. What has to be false for the bull to die?
Question: “Research JNJ as a US-listed name.”. Invert JNJ. Invert: how would this thesis get killed? List the kill-shots before the romance. On file: 10-K FY FY2025; revenue $94.2B; revenue YoY 6.0%; net income $26.8B; ROE 32.9%; LT debt/equity 0.51; P/E 24.1; P/B 7.9; P/S 6.9; price $266.35 cached. Name what must be true for the bull: earnings quality, leverage (0.51), and whether footnotes hide the cycle. If I cannot name the kill path, I am not doing the job. Underwrite frame: Worth further homework.
Counted from isolated briefs. Ratios are filings or cached model input — not a live quote, not a rating, not a buy button.
| Metric | Value | Note |
|---|---|---|
| P/E | 24.1 | P/B, P/S from cached price × diluted shares vs filings. Not a live quote. |
| P/B | 7.94 | P/B, P/S from cached price × diluted shares vs filings. Not a live quote. |
| P/S | 6.87 | — |
| ROE | 32.9% | — |
| LT debt / equity | 0.51 | — |
| Revenue (FY) | $94.2B | — |
| Revenue YoY | +6.0% | — |
| Net income | $26.8B | — |
| Diluted EPS | $11.03 | — |
Cycle, timing, exit, and quant seats are dark on this plan. A three-seat sample cannot locate the cycle or size a position.
Assembly is a second isolated pass over the briefs. Masters did not read each other. Research simulation — not advice, not a buy button.
Analyst unlocks 16 independent seats (16 isolated prompts + 1 assembly pass).
See AnalystCounted from independent briefs only — not a vote, not a recommendation.
Trend research (Wood, Laffont, and the rest of the era desk) is locked on Observer.
Unlocks on Analyst (16). Empty seats stay empty — we do not ghost-fill them.
Compare plansCycle desk (Dalio, Marks, Templeton) is locked on Observer.
Unlocks on Analyst (16). Empty seats stay empty — we do not ghost-fill them.
Compare plansWarren BuffettJNJ: screened alone against Moat & Management Final Review.
Peter LynchJNJ: screened alone against Ten-Bagger Hunter.
Debate starts only after independent briefs exist. Red team still does not see a shared draft.
Charlie Munger — Debate chair · inversion: the best way to kill this thesis
Warren Buffett — Final review · 10-year hold test
Full transcript, risk list, and sizing stay on higher seats.
Unlock more seatsTiming desk (O’Neil and the tape seats) is locked on Observer.
Unlocks on Analyst (16). Empty seats stay empty — we do not ghost-fill them.
Compare plansExit desk (Livermore, Darvas, Bogle accountability) is locked on Observer.
Unlocks on Committee or Partners (61). Empty seats stay empty — we do not ghost-fill them.
Compare plansQuant (Thorp Kelly sizing, then the full seven on Committee) is locked on Observer.
Unlocks on Analyst (16). Empty seats stay empty — we do not ghost-fill them.
Compare plansAgents61 is a research simulation and educational tool. Isolated views, splits, and assembly notes only. Not personalized advice. AI-generated.
